Zobrazeno 1 - 10
of 63
pro vyhledávání: '"инсулин гларгин"'
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 4-16 (2022)
Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulis
Externí odkaz:
https://doaj.org/article/864afcbe094147a9beab69ad5e267701
Autor:
S. K. Zyryanov, I. N. Dyakov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 4-15 (2022)
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are one of the modern options for glycemia control in DM Type 2 a
Externí odkaz:
https://doaj.org/article/a3d973c7b4614d8a91739ad431ebba26
Autor:
I. N. Dyakov, S. K. Zyryanov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 5, Pp 4-14 (2021)
Insulin glargine 100 U/ml (iGla) is gradually giving way to a fixed combination of insulin glargine 100 U/ml+ lixisenatide (iGlaLixi) — an effective and safe drug for Diabetes Mellitus Type 2 (DM2T) control. It has demonstrated the economic benefit
Externí odkaz:
https://doaj.org/article/6232f7df4b864be7935f91493e808d7b
Autor:
I. N. Dyakov, S. K. Zyryanov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 4-15 (2021)
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Agonists of receptors for glucagon like peptide-1 (aGLP-1) are one of the modern option for glycemia control in DM Typ
Externí odkaz:
https://doaj.org/article/2785338f46e3440b9a200a40d238437b
Autor:
I. N. Dyakov, S. K. Zyryanov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 4-15 (2021)
Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evalu
Externí odkaz:
https://doaj.org/article/f6f7de9fabaa4352b76368dc57dd56c4
Autor:
I. N. Dyakov, S. K. Zyryanov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 4-14 (2020)
Second generation insulin analogue — insulin glargine 300 UI/ml (GLA-300) — can provide an effective control of Diabetes Mellitus (DM) with minimal risk of hypoglycemic events and prevent of cardiovascular complications or events (CVS). Pharmacoe
Externí odkaz:
https://doaj.org/article/b21d93d5f0f84f3cb2adba3aa6e2d5ae
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 13-22 (2020)
Aim: a prognosis of clinical-economic efficacy of the fixed combination of insulin glargine and lixisenatide (Soliqua SoloStar®) in comparison with standard therapy with focus on micro- and macrovascular complications of Diabetes Mellitus type 2 (T2
Externí odkaz:
https://doaj.org/article/553a6426cd0e47598d8fec61af138875
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 25-34 (2019)
Insulin therapy is one of the effective methods of effective control of diabetes mellitus type 2 (T2DM) which can manage resistance to insulin. Insulin’s analogs have advantages in compare with human insulins in frames of safety (less amount of hyp
Externí odkaz:
https://doaj.org/article/e2d0486b99644a5795c3238317307ec2
Autor:
S. K. Zyryanov, I. N. Dyakov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 4-14 (2019)
Fixed antidiabetic drugs’ combinations have aim to improve Diabetes Mellitus type 2 (DMT2) control as well as a safety treatment increasing. Soliqua SoloStar® is a new registered drug for control fasting and prandial glucose levels, contained insu
Externí odkaz:
https://doaj.org/article/2949043da2b349a0a83c3e8c90d40dff
Autor:
S. К. Zyryanov, I. N. Dyakov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 4-13 (2019)
Fixed antidiabetic drugs’ combinations have aim to improve of Diabetes Mellitus type 2 (DMT2) control as well as a safety treatment increasing. Soliqua SoloStar® is a new registered drug for control of fasting and prandial glucose levels, containe
Externí odkaz:
https://doaj.org/article/35aad042d19942e2b96e375dc25e8e77